Pyxis Oncology to Present at September Investor and Industry Conferences

Pyxis Oncology will participate in three conferences in September to discuss its ADC therapeutics for cancer. CEO Dr. Lara S. Sullivan will lead presentations and fireside chats at Cantor Global Healthcare, H.C. Wainwright Global Investment, and ADC and Novel Conjugates Partnering and Investment Summits. Live webcasts and replays will be available on the Pyxis Oncology investor relations website.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, has announced its participation in three significant industry conferences in September. The company's President, Chief Executive Officer, and Chief Medical Officer, Dr. Lara S. Sullivan, will lead presentations and fireside chats at the Cantor Global Healthcare Conference, the H.C. Wainwright 27th Annual Global Investment Conference, and the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit. Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website [1].

The Cantor Global Healthcare Conference, scheduled for September 3 in New York, will feature a fireside chat and investor one-on-one meetings with Dr. Sullivan. The H.C. Wainwright 27th Annual Global Investment Conference, taking place on September 8 in New York, will also include a fireside chat and investor one-on-one meetings. The 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit, held on September 9 in Boston, will feature a company presentation by Dr. Sullivan [1].

Pyxis Oncology is currently conducting ongoing Phase 1 clinical studies with its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), in multiple types of solid tumors. The company has a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, Pyxis Oncology has initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors [1].

These upcoming conferences provide an opportunity for investors and industry professionals to gain insights into Pyxis Oncology’s innovative ADC therapeutics and clinical progress. For more information, visit www.pyxisoncology.com or follow the company on Twitter and LinkedIn [1].

References:
[1] https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-participate-september-investor-and-industry